Eidt Daniela, Mittendorf Thomas, Wagner Thomas O F, Reimann Andreas, Graf von der Schulenburg J-Matthias
Forschungsstelle für Gesundheitsökonomie, Leibniz Universität Hannover, Hannover.
Med Klin (Munich). 2009 Jul 15;104(7):529-35. doi: 10.1007/s00063-009-1112-9. Epub 2009 Jul 18.
Main objective of this study is to assess and evaluate resource use in outpatient treatment of cystic fibrosis (CF) in Germany and to compare this with current reimbursement.
Outpatient treatment was evaluated in seven different CF centers.Clinical patient data, resource use, and time consumption were recorded in 2006. A micro-costing approach was used to price resource use data.
Mean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year.
Human resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany.
本研究的主要目的是评估和评价德国囊性纤维化（CF）门诊治疗中的资源使用情况，并将其与当前的报销情况进行比较。
在七个不同的CF中心对门诊治疗进行评估。2006年记录了临床患者数据、资源使用情况和时间消耗。采用微观成本核算方法对资源使用数据进行定价。
每位患者（n = 326）每季度的平均成本为488欧元。薪酬（每位患者每季度252欧元）仅覆盖总成本的52%。此外，还发现患者存在相当大的时间和经济负担，且随着年龄增长生活质量下降。每位患者每年的药物成本为21,604欧元。
如今德国CF中心的人力资源已低于欧洲CF护理标准共识所设定的要求。在德国实现成本覆盖的报销计划对于确保高水平的患者护理至关重要。
